To receive Series A funding from Vantage Ventures, a biotech startup must demonstrate successful Phase I safety trials for its lead drug candidate. BioSphere Therapeutics recently completed its Phase I trials with zero reported adverse events among all trial participants. The company's founders concluded that because they satisfied the firm's mandate by completing Phase I safety trials, Vantage Ventures will definitely approve their application for Series A funding. Which of the following best describes the vulnerability in the founders' reasoning?
- It treats a condition that is necessary for securing funding as though it were sufficient to guarantee that funding.Answer
- BIt presumes without justification that completing Phase I safety trials causes a drug candidate to perform effectively in Phase II efficacy trials.
- CIt relies on a sample of trial participants that is too small to draw statistically sound conclusions regarding long-term drug safety.
- DIt overlooks the possibility that satisfying Phase I safety requirements actually decreases a startup's likelihood of attracting institutional investors.
- EIt fails to consider whether competing venture capital firms offer more favorable investment terms than Vantage Ventures.
Answer
The argument incorrectly treats a necessary prerequisite (completing Phase I safety trials) as a sufficient condition that guarantees funding approval.
The passage establishes that completing Phase I safety trials is a requirement (a necessary condition) for receiving Series A funding from Vantage Ventures. However, the founders conclude that meeting this single requirement guarantees funding approval (treating it as a sufficient condition). The argument fails to consider that other necessary conditions, such as commercial viability or valuation agreements, might also need to be satisfied.
Step-by-Step Solution
Key Concept
Confusing Necessary and Sufficient Conditions